期刊
JOURNAL OF DRUG TARGETING
卷 27, 期 2, 页码 164-173出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/1061186X.2018.1474361
关键词
Drug targets; receptors; neurodegenerative diseases; antagonist; drug development
资金
- NSFC [81471415]
- Scientific Research Program - Shaanxi Provincial Education Department [17JK0666]
Alzheimer's disease (AD) is a chronic neurodegenerative disease, which is considered as one of the most intractable medical problems with heavy social and economic costs. The current drugs for AD, including acetylcholinesterase inhibitors (AChEIs) and memantine, a NMDA receptor antagonist, only temporarily ameliorate cognitive decline, but are unable to stop or reverse the progression of dementia. This paper reviewed the recent advance in AD drug development. The drug discovery programs under clinical trials targeting cholinergic system, alpha 7 nicotinic acetylcholine receptors (nAChRs), N-methyl-d-aspartate receptor (NMDAR), beta-secretase, gamma-secretase modulators, tau, inflammatory mediators and glucagon-like peptide-1 (GLP-1) were discussed. Though several drug discovery programs are ongoing, the high failure rate is an outstanding issue. Novel techniques and strategies are desperately needed to significantly accelerate this process.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据